- Conditions
- Melanoma, Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Drug
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 3
- States / cities
- Billings, Montana • Philadelphia, Pennsylvania • Greenville, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, HCC
- Interventions
- JX-594 recombinant vaccina GM-CSF, Best Supportive Care
- Biological · Other
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- La Jolla, California • Orange, California • San Francisco, California + 8 more
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor, Ewing's Sarcoma
- Interventions
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Drug
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Houston, Texas
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
- Biological
- Lead sponsor
- SillaJen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Irvine, California • Miami, Florida • St Louis, Missouri + 2 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
- Genetic
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 5
- States / cities
- La Jolla, California • Rochester, Minnesota • Billings, Montana + 2 more
- Conditions
- Melanoma
- Interventions
- JX-594
- Biological
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Billings, Montana • Greenville, South Carolina
- Conditions
- Colorectal Carcinoma, CRC
- Interventions
- JX-594, Irinotecan
- Biological · Drug
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • La Jolla, California • Billings, Montana + 3 more
- Conditions
- Hepatocellular Carinoma
- Interventions
- JX-594 recombinant vaccina GM-CSF
- Biological
- Lead sponsor
- Jennerex Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • San Antonio, Texas
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Pexastimogene Devacirepvec (Pexa Vec), Sorafenib
- Biological · Drug
- Lead sponsor
- SillaJen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Orange, California + 19 more
- Conditions
- Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
- Interventions
- BAL0891, Tislelizumab, Paclitaxel
- Drug · Combination Product
- Lead sponsor
- SillaJen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 11
- States / cities
- New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more